LITTLETON, Colo., Oct. 5, 2023 /PRNewswire/ -- Neway, LLC, the U.S. leader in value-based dialysis lab care, today announced a strategic lab services arrangement with Quest Diagnostics (NYSE: DGX) that aims to accelerate dialysis laboratory testing and reduce the laboratory costs of dialysis programs for patients with end-stage renal disease (ESRD).
Under the terms of the agreement, Neway will utilize the extensive lab network of Quest Diagnostics to provide local dialysis laboratory testing services with typically next-day results after arrival at a Quest Diagnostics laboratory. The Neway-Quest collaboration will provide an alternative to the centralized lab model where the majority of dialysis programs in the U.S. transport specimens to a single laboratory for processing. By utilizing Quest's distributed lab network, Neway and its affiliated dialysis centers and their patients will experience faster testing and results reporting and lower transportation costs.
Bryan Thompson, Neway Founder and CEO, said, "The Neway solution exemplifies our dedication to bringing value, innovation, stewardship, and economies of scale to the unique dialysis industry. The centralized dialysis laboratory specimen testing model has been around since the early 1990s with limited innovation. The old model of generally relying on air transportation of dialysis laboratory specimens to a single U.S. location is costly and can takes days for results. The 'new way' for dialysis laboratory testing is a decentralized network of laboratory locations that spans the nation. This approach is good for dialysis patients, dialysis programs, insurance payers, and the entire dialysis industry. It is a win for everyone."
"As a leader in cardiometabolic diagnostic solutions, including in kidney disease, Quest understands the unique challenges patients with ESRD face and the criticality of rapid testing that never compromises on quality," said Mouris Saghir, PhD, Vice President and General Manager for the Quest Diagnostics National Cardiometabolic Center of Excellence at Cleveland HeartLab. "Working together with Neway, we will address these challenges and expedite test results while maintaining the highest level of quality for patients with ESRD."
Last Trade: | US$152.93 |
Daily Change: | -1.30 -0.84 |
Daily Volume: | 650,186 |
Market Cap: | US$17.020B |
August 26, 2024 August 21, 2024 August 15, 2024 August 12, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB